Summary
Cardiovascular disease (CVD) covers a range of difference diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia of which accelerate the development of atherosclerotic plaques building up within blood vessels. As atheroma develops its causes stenosis of the blood vessels which can restrict blood flow to the body, brain or heart depending on its locale. It is also possible for the fibrous cap of the plaque to break off, triggering the coagulation cascade and causing a thrombus to form locally which can completely occlude blood flow.
The treatments of CVD typically focus on prevention by controlling the risk factors of CVD. As such, the treatments usually fall within three categories: Anti-hypertensives aim to lower blood pressure; anti-dyslipidemia drugs aim to alter lipid levels to an acceptable range; and anti-thrombotic drugs aim to either prevent thrombus forming or work to mitigate the damage of a current thrombi, they do this by either interrupting the coagulation cascade or inhibiting platelet aggregation, both of which inhibit blood from clotting.
There are over 1,200 pipeline products within the CVD therapy area. Over 50% of these products are small molecules however there is also diversification with regards to molecule types within the pipeline. In addition, the molecular targets in the pipeline are considerably diverse with a high frequency of products acting on targets related to lipid metabolism and those which act on elements of the coagulation cascade.
Among those pipeline drugs expected for imminent release to market there is a mixture of first-in-class products, typically anti-dyslipidemia drugs aiming to provide alternatives to statin therapy, and drugs belonging to currently popular classes such as PCSK9 inhibitors and direct factor Xa inhibitors.
The report provides comprehensive information on the pipeline development landscape for Hypertension, Dyslipidemia, Venous thromboembolism and Heart failure, from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.
Scope
- Which companies are the most active within the pipeline for CVD?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
'
Table of Contents
GBI Research Report Guidance 2
Executive Summary 3
Table of Contents 4
List of Tables 6
List of Figures 15
Introduction 18
Cardiovascular Disorders Report Coverage 18
Hypertension Overview 18
Dyslipidemia Overview 18
Thromboembolism Overview 18
Heart Failure Overview 18
Therapeutics Development 20
Hypertension 20
Dyslipidemia 22
Thromboembolism 24
Heart Failure 26
Therapeutics under Development by Companies 31
Hypertension 31
Dyslipidemia 35
Thromboembolism 39
Heart Failure 40
Therapeutics under Investigation by Universities/Institutes 47
Hypertension 47
Dyslipidemia 49
Thromboembolism 50
Heart Failure 50
Pipeline Products Glance 52
Hypertension 52
Dyslipidemia 55
Thromboembolism 58
Heart Failure 61
Products under Development by Companies 68
Hypertension 68
Dyslipidemia 75
Thromboembolism 79
Heart Failure 79
Products under Investigation by Universities/Institutes 86
Hypertension 86
Dyslipidemia 87
Thromboembolism 88
Heart Failure 88
Companies Involved in Therapeutics Development 90
Hypertension 90
Dyslipidemia 151
Thromboembolism 185
Heart Failure 192
Therapeutics Assessment 244
Hypertension 244
Dyslipidemia 265
Thromboembolism 281
Heart Failure 290
Dormant Projects 325
Hypertension 325
Dyslipidemia 335
Thromboembolism 343
Heart Failure 343
Discontinued Products 349
Hypertension 349
Dyslipidemia 351
Thromboembolism 353
Heart Failure 353
Product Development Milestones 356
Hypertension 356
Dyslipidemia 367
Thromboembolism 379
Heart Failure 396
Appendix 431
Methodology 431
Coverage 431
Secondary Research 431
Primary Research 431
Expert Panel Validation 431
Contact Us 432
Disclaimer 432
List of Tables
Number of Products under Development for Hypertension 20
Number of Products under Development for Hypertension - Comparative Analysis 21
Number of Products under Development for Dyslipidemia 22
Number of Products under Development for Dyslipidemia - Comparative Analysis 23
Number of Products under Development for Thromboembolism 24
Number of Products under Development for Thromboembolism - Comparative Analysis 25
Number of Products under Development for Acute Heart Failure 26
Number of Products under Development for Congestive Heart Failure (Heart Failure) 27
Number of Products under Development for Congestive Heart Failure (Heart Failure) - Comparative Analysis 28
Number of Products under Development for Chronic Heart Failure 29
Number of Products under Development for Chronic Heart Failure - Comparative Analysis 30
Number of Products under Development by Companies, Hypertension 31
Number of Products under Development by Companies, Dyslipidemia 36
Number of Products under Development by Companies, Thromboembolism 39
Number of Products under Development by Companies, Acute Heart Failure 40
Number of Products under Development by Companies, Congestive Heart Failure (Heart Failure) 42
Number of Products under Development by Companies, Chronic Heart Failure 46
Number of Products under Investigation by Universities/Institutes, Hypertension 48
Number of Products under Investigation by Universities/Institutes, Dyslipidemia 49
Number of Products under Investigation by Universities/Institutes, Thromboembolism 50
Number of Products under Investigation by Universities/Institutes, Congestive Heart Failure (Heart Failure) 51
Number of Products under Investigation by Universities/Institutes, Chronic Heart Failure 51
Comparative Analysis by Late Stage Development, Hypertension 52
Comparative Analysis by Clinical Stage Development, Hypertension 53
Comparative Analysis by Early Stage Development, Hypertension 54
Comparative Analysis by Late Stage Development, Dyslipidemia 55
Comparative Analysis by Clinical Stage Development, Dyslipidemia 56
Comparative Analysis by Early Stage Development, Dyslipidemia 57
Comparative Analysis by Unknown Stage Development, Dyslipidemia 58
Comparative Analysis by Late Stage Development, Thromboembolism 58
Comparative Analysis by Clinical Stage Development, Thromboembolism 59
Comparative Analysis by Early Stage Development, Thromboembolism 60
Comparative Analysis by Late Stage Development, Acute Heart Failure 61
Comparative Analysis by Clinical Stage Development, Acute Heart Failure 61
Comparative Analysis by Early Stage Development, Acute Heart Failure 62
Comparative Analysis by Late Stage Development, Congestive Heart Failure (Heart Failure) 62
Comparative Analysis by Clinical Stage Development, Congestive Heart Failure (Heart Failure) 63
Comparative Analysis by Early Stage Development, Congestive Heart Failure (Heart Failure) 64
Comparative Analysis by Unknown Stage Development, Congestive Heart Failure (Heart Failure) 65
Comparative Analysis by Late Stage Development, Chronic Heart Failure 65
Comparative Analysis by Clinical Stage Development, Chronic Heart Failure 66
Comparative Analysis by Early Stage Development, Chronic Heart Failure 67
Products under Development by Companies, Hypertension 68
Products under Development by Companies, Dyslipidemia 75
Products under Development by Companies, Thromboembolism 79
Products under Development by Companies, Acute Heart Failure 79
Products under Development by Companies, Congestive Heart Failure (Heart Failure) 80
Products under Development by Companies, Chronic Heart Failure 85
Products under Investigation by Universities/Institutes, Hypertension 86
Products under Investigation by Universities/Institutes, Dyslipidemia 87
Products under Investigation by Universities/Institutes, Thromboembolism 88
Products under Investigation by Universities/Institutes, Congestive Heart Failure (Heart Failure) 88
Products under Investigation by Universities/Institutes, Chronic Heart Failure 89
Hypertension - Pipeline by A1M Pharma AB 90
Hypertension - Pipeline by AbbVie Inc 90
Hypertension - Pipeline by Actelion Ltd 91
Hypertension - Pipeline by Afferent Pharmaceuticals Inc 91
Hypertension - Pipeline by Alnylam Pharmaceuticals Inc 92
Hypertension - Pipeline by Anacor Pharmaceuticals Inc 93
Hypertension - Pipeline by AnGes MG Inc 94
Hypertension - Pipeline by APT Therapeutics Inc 94
Hypertension - Pipeline by Arena Pharmaceuticals Inc 95
Hypertension - Pipeline by Ascendis Pharma A/S 96
Hypertension - Pipeline by Asklepion Pharmaceuticals LLC 97
Hypertension - Pipeline by AVEO Pharmaceuticals Inc 97
Hypertension - Pipeline by Bayer AG 98
Hypertension - Pipeline by Bial - Portela & Ca SA 98
Hypertension - Pipeline by Biolab Farmaceutica Ltda 99
Hypertension - Pipeline by BioRestorative Therapies Inc 99
Hypertension - Pipeline by Boryung Pharmaceutical Co Ltd 100
Hypertension - Pipeline by Cellceutix Corp 100
Hypertension - Pipeline by Celsion Corp 101
Hypertension - Pipeline by Celtaxsys Inc 101
Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp 102
Hypertension - Pipeline by CJ HealthCare Corp 102
Hypertension - Pipeline by Complexa Inc 103
Hypertension - Pipeline by Conatus Pharmaceuticals Inc 103
Hypertension - Pipeline by Corion Biotech Srl 104
Hypertension - Pipeline by Cumberland Pharmaceuticals Inc 104
Hypertension - Pipeline by Cytokinetics Inc 105
Hypertension - Pipeline by Daewoong Pharmaceutical Co Ltd 106
Hypertension - Pipeline by Daiichi Sankyo Company Ltd 107
Hypertension - Pipeline by DiaMedica Inc 107
Hypertension - Pipeline by Eli Lilly and Company 108
Hypertension - Pipeline by Esperion Therapeutics Inc 108
Hypertension - Pipeline by F. Hoffmann-La Roche Ltd 109
Hypertension - Pipeline by Ferring International Center SA 109
Hypertension - Pipeline by Galectin Therapeutics Inc 110
Hypertension - Pipeline by Genextra Spa 110
Hypertension - Pipeline by Gilead Sciences Inc 111
Hypertension - Pipeline by GlaxoSmithKline Plc 112
Hypertension - Pipeline by Glenveigh Medical LLC 112
Hypertension - Pipeline by HanAll Biopharma Co Ltd 113
Hypertension - Pipeline by Hanmi Pharmaceuticals Co Ltd 114
Hypertension - Pipeline by HitGen LTD 114
Hypertension - Pipeline by Innopharmax Inc 115
Hypertension - Pipeline by Insmed Inc 115
Hypertension - Pipeline by INVENT Pharmaceuticals Inc 116
Hypertension - Pipeline by Ionis Pharmaceuticals Inc 116
Hypertension - Pipeline by Ironwood Pharmaceuticals Inc 117
Hypertension - Pipeline by Jeil Pharmaceutical Co Ltd 118
Hypertension - Pipeline by Johnson & Johnson 119
Hypertension - Pipeline by JW Pharmaceutical Corp 120
Hypertension - Pipeline by Kowa Company Ltd 120
Hypertension - Pipeline by Leading BioSciences Inc 121
Hypertension - Pipeline by Lee's Pharmaceutical Holdings Ltd 121
Hypertension - Pipeline by Les Laboratoires Servier SAS 122
Hypertension - Pipeline by LFB SA 122
Hypertension - Pipeline by LG Life Science LTD 123
Hypertension - Pipeline by LinXis BV 123
Hypertension - Pipeline by Liquidia Technologies Inc 124
Hypertension - Pipeline by Lotus Pharmaceutical Co Ltd 124
Hypertension - Pipeline by MannKind Corp 125
Hypertension - Pipeline by Mast Therapeutics Inc 125
Hypertension - Pipeline by Merck & Co Inc 126
Hypertension - Pipeline by Mezzion Pharma Co Ltd 126
Hypertension - Pipeline by miRagen Therapeutics Inc 127
Hypertension - Pipeline by Mitsubishi Tanabe Pharma Corp 127
Hypertension - Pipeline by Morphogen-IX Ltd 128
Hypertension - Pipeline by Neurim Pharmaceuticals Ltd 128
Hypertension - Pipeline by Nippon Kayaku Co Ltd 129
Hypertension - Pipeline by Nippon Shinyaku Co Ltd 130
Hypertension - Pipeline by Novartis AG 131
Hypertension - Pipeline by Noxamet Ltd 131
Hypertension - Pipeline by Omeros Corp 132
Hypertension - Pipeline by Peloton Therapeutics Inc 132
Hypertension - Pipeline by Pfizer Inc 133
Hypertension - Pipeline by PhaseBio Pharmaceuticals Inc 133
Hypertension - Pipeline by Pluristem Therapeutics Inc 134
Hypertension - Pipeline by Polyphor Ltd 134
Hypertension - Pipeline by Proteo Inc 135
Hypertension - Pipeline by Pulmokine Inc 135
Hypertension - Pipeline by Quantum Genomics SA 136
Hypertension - Pipeline by Reata Pharmaceuticals Inc 136
List of Figures
Number of Products under Development for Hypertension 20
Number of Products under Development for Hypertension - Comparative Analysis 21
Number of Products under Development for Dyslipidemia 22
Number of Products under Development for Dyslipidemia - Comparative Analysis 23
Number of Products under Development for Thromboembolism 24
Number of Products under Development for Thromboembolism - Comparative Analysis 25
Number of Products under Development for Acute Heart Failure 26
Number of Products under Development for Congestive Heart Failure (Heart Failure) 27
Number of Products under Development for Congestive Heart Failure (Heart Failure) - Comparative Analysis 28
Number of Products under Development for Chronic Heart Failure 29
Number of Products under Development for Chronic Heart Failure - Comparative Analysis 30
Number of Products under Development by Companies, Hypertension 31
Number of Products under Development by Companies, Dyslipidemia 35
Number of Products under Development by Companies, Thromboembolism 39
Number of Products under Development by Companies, Acute Heart Failure 40
Number of Products under Development by Companies, Congestive Heart Failure (Heart Failure) 41
Number of Products under Development by Companies, Chronic Heart Failure 45
Number of Products under Investigation by Universities/Institutes, Hypertension 47
Number of Products under Investigation by Universities/Institutes, Dyslipidemia 49
Number of Products under Investigation by Universities/Institutes, Congestive Heart Failure (Heart Failure) 50
Comparative Analysis by Late Stage Development, Hypertension 52
Comparative Analysis by Clinical Stage Development, Hypertension 53
Comparative Analysis by Early Stage Products, Hypertension 54
Comparative Analysis by Late Stage Development, Dyslipidemia 55
Comparative Analysis by Clinical Stage Development, Dyslipidemia 56
Comparative Analysis by Early Stage Products, Dyslipidemia 57
Comparative Analysis by Late Stage Development, Thromboembolism 58
Comparative Analysis by Clinical Stage Development, Thromboembolism 59
Comparative Analysis by Early Stage Products, Thromboembolism 60
Comparative Analysis by Clinical Stage Development, Acute Heart Failure 61
Comparative Analysis by Late Stage Development, Congestive Heart Failure (Heart Failure) 62
Comparative Analysis by Clinical Stage Development, Congestive Heart Failure (Heart Failure) 63
Comparative Analysis by Early Stage Products, Congestive Heart Failure (Heart Failure) 64
Comparative Analysis by Clinical Stage Development, Chronic Heart Failure 66
Comparative Analysis by Early Stage Products, Chronic Heart Failure 67
Assessment by Monotherapy Products, Hypertension 244
Assessment by Combination Products, Hypertension 245
Number of Products by Top 10 Targets, Hypertension 246
Number of Products by Stage and Top 10 Targets, Hypertension 246
Number of Products by Top 10 Mechanism of Actions, Hypertension 254
Number of Products by Stage and Top 10 Mechanism of Actions, Hypertension 254
Number of Products by Top 10 Routes of Administration, Hypertension 262
Number of Products by Stage and Top 10 Routes of Administration, Hypertension 262
Number of Products by Top 10 Molecule Types, Hypertension 264
Number of Products by Stage and Top 10 Molecule Types, Hypertension 264
Assessment by Monotherapy Products, Dyslipidemia 265
Assessment by Combination Products, Dyslipidemia 267
Number of Products by Top 10 Targets, Dyslipidemia 268
Number of Products by Stage and Top 10 Targets, Dyslipidemia 268
Number of Products by Top 10 Mechanism of Actions, Dyslipidemia 273
Number of Products by Stage and Top 10 Mechanism of Actions, Dyslipidemia 273
Number of Products by Routes of Administration, Dyslipidemia 278
Number of Products by Stage and Routes of Administration, Dyslipidemia 278
Number of Products by Molecule Types, Dyslipidemia 280
Number of Products by Stage and Molecule Types, Dyslipidemia 280
Assessment by Monotherapy Products, Thromboembolism 281
Number of Products by Targets, Thromboembolism 283
Number of Products by Stage and Targets, Thromboembolism 283
Number of Products by Mechanism of Actions, Thromboembolism 285
Number of Products by Stage and Mechanism of Actions, Thromboembolism 285
Number of Products by Routes of Administration, Thromboembolism 287
Number of Products by Stage and Routes of Administration, Thromboembolism 287
Number of Products by Molecule Types, Thromboembolism 289
Number of Products by Stage and Molecule Types, Thromboembolism 289
Assessment by Monotherapy Products, Acute Heart Failure 290
Number of Products by Top 10 Targets, Acute Heart Failure 292
Number of Products by Stage and Top 10 Targets, Acute Heart Failure 292
Number of Products by Top 10 Mechanism of Actions, Acute Heart Failure 294
Number of Products by Stage and Top 10 Mechanism of Actions, Acute Heart Failure 294
Number of Products by Routes of Administration, Acute Heart Failure 296
Number of Products by Stage and Routes of Administration, Acute Heart Failure 296
Number of Products by Molecule Types, Acute Heart Failure 298
Number of Products by Stage and Molecule Types, Acute Heart Failure 298
Assessment by Monotherapy Products, Congestive Heart Failure (Heart Failure) 299
Number of Products by Top 10 Targets, Congestive Heart Failure (Heart Failure) 300
Number of Products by Stage and Top 10 Targets, Congestive Heart Failure (Heart Failure) 301
Number of Products by Top 10 Mechanism of Actions, Congestive Heart Failure (Heart Failure) 307
Number of Products by Stage and Top 10 Mechanism of Actions, Congestive Heart Failure (Heart Failure) 307
Number of Products by Top 10 Routes of Administration, Congestive Heart Failure (Heart Failure) 313
Number of Products by Stage and Top 10 Routes of Administration, Congestive Heart Failure (Heart Failure) 313
Number of Products by Top 10 Molecule Types, Congestive Heart Failure (Heart Failure) 315
Number of Products by Stage and Top 10 Molecule Types, Congestive Heart Failure (Heart Failure) 315
Assessment by Monotherapy Products, Chronic Heart Failure 316
Number of Products by Top 10 Targets, Chronic Heart Failure 318
Number of Products by Stage and Top 10 Targets, Chronic Heart Failure 318
Number of Products by Top 10 Mechanism of Actions, Chronic Heart Failure 320
Number of Products by Stage and Top 10 Mechanism of Actions, Chronic Heart Failure 320
Number of Products by Routes of Administration, Chronic Heart Failure 322
Number of Products by Stage and Routes of Administration, Chronic Heart Failure 322
Number of Products by Molecule Types, Chronic Heart Failure 324
Number of Products by Stage and Molecule Types, Chronic Heart Failure 324
